On April 15, 2022 GC Genome, a leading company in Genomic Diagnostics, reported that the company presented the deep learning algorithm that detects and classifies multi-cancer using cf-WGS (cell free DNA whole genome sequencing), summarized in a poster session held at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2022 in New Orleans, Louisiana (Press release, GC Genome, APR 15, 2022, View Source [SID1234612320]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The data from the presentation show that it detects abnormal patterns of cancer more sensitively and accurately than original liquid biopsy as it applies deep learning algorithm on whole genome sequencing data, which uncovers structural variants with distinct tumor type.
In addition, this biopsy can detect the existence of 9 major cancers (△ lung cancer △ colorectal cancer △ breast cancer △liver cancer △ pancreatic cancer △ cholangiocarcinoma △ head and neck cancer △ ovarian cancer △ esophageal cancer) through whole genome sequencing (WGS) from circulating tumor DNA (ctDNA) in the blood. Further, its ‘Multi-cancer prediction’ model can predict the tumor-derived tissues related to the 6 specific types of cancers. (△ lung cancer △ breast cancer △ liver cancer △ pancreatic cancer △ ovarian cancer △ esophageal cancer)
"We are excited to introduce the AI-based liquid biopsy with GC Genome’s original technology applied," said Eun-Hae Cho, Chief Technology Officer at GC Genome Research Center, "The data to be presented at this year’s AACR (Free AACR Whitepaper) meeting demonstrates a major step forward in our commitment to offering clinicians and patients a highly sensitive multi-cancer screening test where we believe cancer screening can save lives."